| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 2,650 |
| 2 | Nanoparticles in Photodynamic Therapy | Chemical Reviews | 2015 | 2,598 |
| 3 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | Nature | 2016 | 1,584 |
| 4 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Lancet, The | 2005 | 1,453 |
| 5 | The landscape of cancer genes and mutational processes in breast cancer | Nature | 2012 | 1,196 |
| 6 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer | Annals of Oncology | 2021 | 1,105 |
| 7 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates | Nature | 2018 | 1,028 |
| 8 | The Simons Genome Diversity Project: 300 genomes from 142 diverse populations | Nature | 2016 | 976 |
| 9 | Nasopharyngeal carcinoma | Lancet, The | 2016 | 950 |
| 10 | NK cells for cancer immunotherapy | Nature Reviews Drug Discovery | 2020 | 935 |
| 11 | Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Nature | 2011 | 916 |
| 12 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial | Lancet Oncology, The | 2016 | 895 |
| 13 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Lancet, The | 2017 | 873 |
| 14 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial | Lancet Oncology, The | 2022 | 867 |
| 15 | Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Nature | 2010 | 858 |
| 16 | Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors | Nature Genetics | 2017 | 801 |
| 17 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) | European Journal of Immunology | 2019 | 765 |
| 18 | Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma | Cancer Discovery | 2017 | 723 |
| 19 | Redefining Palliative Care—A New Consensus-Based Definition | Journal of Pain and Symptom Management | 2020 | 722 |
| 20 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Lancet Oncology, The | 2012 | 701 |
| 21 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Annals of Oncology | 2018 | 642 |
| 22 | Cholangiocarcinoma | Nature Reviews Disease Primers | 2021 | 620 |
| 23 | Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations | Journal of Clinical Oncology | 2022 | 600 |
| 24 | Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms | Cancer Gene Therapy | 2020 | 591 |
| 25 | Isolation and retrieval of circulating tumor cells using centrifugal forces | Scientific Reports | 2013 | 575 |
| 26 | Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner | Cell | 2018 | 569 |
| 27 | Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis | Lancet Oncology, The | 2015 | 553 |
| 28 | Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma | Cell | 2020 | 530 |
| 29 | Molecular landmarks of tumor hypoxia across cancer types | Nature Genetics | 2019 | 502 |
| 30 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer | Journal of Thoracic Oncology | 2021 | 490 |
| 31 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC | Journal of Thoracic Oncology | 2018 | 478 |
| 32 | Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease | Immunity | 2021 | 469 |
| 33 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets | Gut | 2012 | 457 |
| 34 | Biological response of cancer cells to radiation treatment | Frontiers in Molecular Biosciences | 2014 | 454 |
| 35 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Nature Medicine | 2022 | 454 |
| 36 | Global Epidemiology and Genetics of Hepatocellular Carcinoma | Gastroenterology | 2023 | 451 |
| 37 | Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells | Lab on A Chip | 2014 | 450 |
| 38 | Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes | Nature Genetics | 2012 | 438 |
| 39 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Annals of Oncology | 2018 | 427 |
| 40 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy | Cells | 2020 | 424 |
| 41 | The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy | Journal of Hematology and Oncology | 2020 | 401 |
| 42 | Non-small-cell lung cancer | Nature Reviews Disease Primers | 2024 | 398 |
| 43 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | Annals of Oncology | 2017 | 396 |
| 44 | A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer | Nature Medicine | 2012 | 395 |
| 45 | Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) | Thoracic Cancer | 2020 | 392 |
| 46 | Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology | 2017 | 390 |
| 47 | Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers | Nature Genetics | 2013 | 388 |
| 48 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Lancet Oncology, The | 2020 | 383 |
| 49 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) | European Journal of Immunology | 2021 | 381 |
| 50 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 380 |
